Weeks out from an $80M launch, a pain and CNS startup is back with a fresh raise. Can an IPO be far behind?
Not two months after launching out of RA Capital’s incubator, Eliem Therapeutics is returning to the firm — and others — to raise another heap of cash. And this time, an IPO could potentially be in the works.
Eliem has put together a $60 million Series B round co-led by RA Capital as it seeks to further advance two lead clinical candidates across four trials. The biotech declined an interview and further declined to comment on an emailed question regarding financing plans, suggesting they may be hunkering down in preparation for an S-1 filing with the SEC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.